ro4

Ro 4-6824 is a biochemical with immunosuppressive action.

[D-Pro4,D-Trp7,9,10] Substance P (4-11) serves as a potent antagonist of the tachykinin family of neuropeptides [1].

[D-Pro4,D-Trp7,9] Substance P (4-11) acts as a potent antagonist to Substance P, significantly reducing plasma aldosterone (ALDO) concentrations[1].

RO4988546 is a potent negative allosteric modulator of mGlu₂/₃.

RO4927350 is a potent and highly selective non-ATP-competitive MEK1/2 inhibitor. RO4927350 selectively blocks the MAPK pathway signaling both in vitro and in vivo, which results in significant antitumor efficacy in a broad spectrum of tumor models. RO4927350 inhibits not only ERK1/2 but also MEK1/2 phosphorylation. In cancer cells, high basal levels of phospho-MEK1/2 rather than phospho-ERK1/2 seem to correlate with greater sensitivity to RO4927350. Furthermore, RO4927350 prevents a feedback increase in MEK phosphorylation, which has been observed with other MEK inhibitors. RO4927350 represents a novel therapeutic modality in cancers with aberrant MAPK pathway activation.

[D-Pro4,D-Trp7,9,Nle11] Substance P (4-11) is a potent neurokinin NK1 antagonist that effectively inhibits the actions of gold-protein-substance P (GPSP) and substance P (SP), demonstrating its efficacy in neutralizing their effects [1].

RO4987655 (RG7167) is an orally active and highly selective MEK inhibitor (IC50: 5.2 nM for MEK1/MEK2).

RO4583298 is a highly potent dual NK1/NK3 receptor antagonist with in vivo activity.

Ro4491533 is a potent and selective negative allosteric modulator for group II of the metabotropic glutamate receptors (mGluR2/3).

RO4929097 (RG-4733), a γ secretase inhibitor (IC50: 4 nM), inhibits cellular processing of Aβ40 and Notch (EC50: 14/5 nM).

RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays

AF-353 (Ro-4), an effective and orally bioavailable antagonist of the P2X3/P2X2/3 receptor, inhibits human and rat P2X3 (pIC50= 8.0).